The growth in prescription drug costs covered by employers and Rx plan sponsors are driving them to adopt a long list of utilization management and price-tiering strategies looking to 2012, according to the 2011-2012 Prescription Drug Benefit Cost and Plan Design Report, sponsored by Takeda Pharmaceuticals. The average drug trend for 2011 — that is, [...]
Archive | Bio/life sciences RSS feed for this section
Making health care cheaper: innovating for and beyond the safety net
The big opportunity for investing in health innovation is in cost-reducing technologies, according to the seven essays that make up Innovating More Affordable Health Care, a supplement to the Stanford Social Innovation Review, sponsored by The California HealthCare Foundation (CHCF). The big disconnect in getting innovation adopted in the U.S. health system is the misalignment between risks (what [...]
Patients feel out of the Rx drug development process: why participatory health in pharma is important
“Value” in prescription drugs is first and foremost about outcomes, in the eyes of physicians and biopharma. For managed care, “value” is first about safety, then patient outcomes. However, although one-third of patients managing a chronic condition cannot define ”value” in health care, 9 in 10 say that prescription drugs are “valuable” to their health and wellbeing. In [...]
Don’t assume generics will stop drug cost trends in 2012 and beyond: specialty drugs will drive growing Rx spending
In the 2011 Medco Drug Trend Report, there’s good news and bad news depending on the lens you wear as a health care stakeholder in the U.S. On the positive side of the ledger, for consumers, payers and health plan sponsors, drug trend in 2010 stayed fairly flat at 3.7% growth. That’s due in major [...]
Patient perspectives should be part of evidence-based medicine, Dr. Weil et al say
Randomized controlled trials (RCTs) have been the rational cornerstone of medical decision making for decades. RCTs demonstrate a drug or therapeutic course’s efficacy – that is, the extent to which a specific intervention, procedure, or regimen produces a beneficial result under ideal conditions. Of course, how a particular therapy works in an individual is highly personalized [...]
About Jane & Health Populi
Jane Sarasohn-Kahn is a health economist and management consultant that serves clients at the intersection of health and technology.
Her clients include all stakeholders in health, including providers, payors and plans; companies in biopharma, medical devices, financial services, technology and consumer goods; non-profits and NGOs. Jane's lens on health is best-defined by the World Health Organization: health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity.
-
ePatients: a connected, collaborative, creating community
-
Patients want online communication with doctors, and more clinicians are listening
-
Meeker & Murphy on Mobile – through the lens of health
-
Patient Power Through Data Liberación, and Private Sector to the Rescue – Health 2.0 DC Takeaways
-
iPads and health care – health IT managers slow down physicians’ clinical adoption
- The state of health IT in America: thinking about the Bipartisan Policy Center report on health IT
-
From volume to value: how health execs see the future of health care
-
We are all health illiterates: navigating the health system in a sea of paper and financial haze
- From Volume to Value: How Health Execs See the Future of Health Care | Care And Cost: [...] Posted 1/31/12 on Health Populi [...]...
-
leslie barretta: In a land of fragmented, decentralized health care...
-
Tomer Shoval: Health literacy is a big obstacle for anyone who w...
-
Aaron: That is such a pain! So much paper, so little time...
